Scientific KnowledgeLooking for development status?Clinical stage, comparable drugs/devices, and estimated availability are tracked in the Therapy Pipeline.
NHPN-1010
Synaptic protection + neuroinflammation reduction (HPN-07 + NAC)
Evidence level
No primary evidence catalogued yet
How it works
An oral combination of HPN-07 and N-acetylcysteine (originally Otologic Pharmaceutics, licensed to Oblato Inc.) designed to protect and help regenerate nerve endings damaged by noise, targeting the cochlear nerve loss the Cochlear Synaptopathy hypothesis implicates. Phase 1 showed good safety, but Phase 2 has never started for lack of funding, so there is no tinnitus efficacy data.
This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.
Explore connections· click any item to explore
Targets1